Drug intelligence / Profile preview

LTV-1

Development stage: Preclinical
Lead developer: Sanford Burnham Prebys Medical Discovery Institute
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

LTV-1 is an experimental small-molecule antagonist of the protein tyrosine phosphatase non-receptor type 22 (PTPN22), a negative regulator of T-cell receptor signaling that is genetically implicated in multiple autoimmune diseases. By inhibiting PTPN22, LTV-1 is intended to enhance T-cell activation and modulate immune responses, with potential applications across autoimmune and inflammatory indications. The compound was initially developed at the Sanford Burnham Prebys Medical Discovery Institute and remains in very early, preclinical research with no active clinical development reported.

Targets

PTPN22 (Protein tyrosine phosphatase non-receptor type 22)

Beyond the preview

Go deeper on LTV-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTV-1.

Explore the full profile